Skip to main content

β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling.

Publication ,  Journal Article
Tilley, DG; Zhu, W; Myers, VD; Barr, LA; Gao, E; Li, X; Song, J; Carter, RL; Makarewich, CA; Yu, D; Troupes, CD; Grisanti, LA; Coleman, RC ...
Published in: Circulation
November 11, 2014

BACKGROUND: Enhanced arginine vasopressin levels are associated with increased mortality during end-stage human heart failure, and cardiac arginine vasopressin type 1A receptor (V1AR) expression becomes increased. Additionally, mice with cardiac-restricted V1AR overexpression develop cardiomyopathy and decreased β-adrenergic receptor (βAR) responsiveness. This led us to hypothesize that V1AR signaling regulates βAR responsiveness and in doing so contributes to development of heart failure. METHODS AND RESULTS: Transaortic constriction resulted in decreased cardiac function and βAR density and increased cardiac V1AR expression, effects reversed by a V1AR-selective antagonist. Molecularly, V1AR stimulation led to decreased βAR ligand affinity, as well as βAR-induced Ca(2+) mobilization and cAMP generation in isolated adult cardiomyocytes, effects recapitulated via ex vivo Langendorff analysis. V1AR-mediated regulation of βAR responsiveness was demonstrated to occur in a previously unrecognized Gq protein-independent/G protein receptor kinase-dependent manner. CONCLUSIONS: This newly discovered relationship between cardiac V1AR and βAR may be informative for the treatment of patients with acute decompensated heart failure and elevated arginine vasopressin.

Duke Scholars

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

November 11, 2014

Volume

130

Issue

20

Start / End Page

1800 / 1811

Location

United States

Related Subject Headings

  • Second Messenger Systems
  • Rolipram
  • Recombinant Fusion Proteins
  • Receptors, Vasopressin
  • Receptors, Adrenergic, beta
  • Pyrrolidines
  • Myocardial Contraction
  • Mutagenesis, Site-Directed
  • Mice, Transgenic
  • Mice, Inbred C57BL
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tilley, D. G., Zhu, W., Myers, V. D., Barr, L. A., Gao, E., Li, X., … Feldman, A. M. (2014). β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling. Circulation, 130(20), 1800–1811. https://doi.org/10.1161/CIRCULATIONAHA.114.010434
Tilley, Douglas G., Weizhong Zhu, Valerie D. Myers, Larry A. Barr, Erhe Gao, Xue Li, Jianliang Song, et al. “β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling.Circulation 130, no. 20 (November 11, 2014): 1800–1811. https://doi.org/10.1161/CIRCULATIONAHA.114.010434.
Tilley DG, Zhu W, Myers VD, Barr LA, Gao E, Li X, et al. β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling. Circulation. 2014 Nov 11;130(20):1800–11.
Tilley, Douglas G., et al. “β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling.Circulation, vol. 130, no. 20, Nov. 2014, pp. 1800–11. Pubmed, doi:10.1161/CIRCULATIONAHA.114.010434.
Tilley DG, Zhu W, Myers VD, Barr LA, Gao E, Li X, Song J, Carter RL, Makarewich CA, Yu D, Troupes CD, Grisanti LA, Coleman RC, Koch WJ, Houser SR, Cheung JY, Feldman AM. β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling. Circulation. 2014 Nov 11;130(20):1800–1811.

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

November 11, 2014

Volume

130

Issue

20

Start / End Page

1800 / 1811

Location

United States

Related Subject Headings

  • Second Messenger Systems
  • Rolipram
  • Recombinant Fusion Proteins
  • Receptors, Vasopressin
  • Receptors, Adrenergic, beta
  • Pyrrolidines
  • Myocardial Contraction
  • Mutagenesis, Site-Directed
  • Mice, Transgenic
  • Mice, Inbred C57BL